Business Standard
Sunday, Nov 22, 2009
 
drived banner
drived banner
  Advanced Search
Feedback | RSS
Content Guide
Follow us on  
||Companies & Industry||||||| 
 Section Home | News Now | Today's Paper | Q&A | People in the News | Industry News | Features | The Compass | Research & Analysis | Opinion | Corporate Results
Home > Companies & Industry Live Markets | Smart Portfolios II
  Search:

Terror strike: Drug firms may lose outsourcing deals
BS Reporter / Mumbai November 29, 2008, 0:40 IST

Indian drug makers may lose out on outsourcing contracts as overseas pharmaceutical companies defer their visits to the country in the wake of Mumbai terror attacks, according to industry experts.

 
 
News Now
Paper
Specials
- Sensex makes remarkable recovery, regains 17K
- US sleuths believe ISI had links with Headley
- India not worried about US honouring n-deal: PM
- Vendata expects quick nod for Orissa project
- Life insurance ind to clock Rs 2.5 lakh cr premium
More  

''The drug industry could see short-term setbacks, especially in the field of outsourcing,’’ said Sujay Shetty, head of Life Sciences, PricewaterhouseCoopers. ''Executives of global companies may be asked to refrain from coming to India and many planned visits have been cancelled.’’

Already, CPhI India, one of the largest global industry exhibitions that provides the drug makers an opportunity to secure contracts, has been postponed. The three-day exhibition was scheduled to begin at Bombay Exhibition Centre today. P-MEC India, a prominent event for the pharmaceutical machinery and equipment industry that was scheduled to begin at the same venue yesterday, has also been postponed.

''This decision has been taken in consultation with the industry and local authorities in the interest of the safety and security of visitors and exhibitors alike," informed the organisers CMP Information, a part of the London-based United Business Media (UBM).

"Such repeated terrorist attacks will mar our business prospects, especially from Fortune 500 companies, who are closely observing the developments. Apart from the global meltdown, this will add more worries to our economic growth," said Ranjit Shahani, president, Indian Merchant's Chamber and vice-chairman and managing director of Novartis India.

Meanwhile, attendance was thin at the offices of most of the Mumbai drug makers for the second consecutive day today, said company sources. Pharma companies such as Wockhardt, Cipla, Lupin and Glenmark had closed their offices on Thursday following a series of terrorist attacks in Mumbai since Wednesday night. Industry sources said though the attacks may have an impact in the short-term, there will not have any long-term effect.

"This is a very unfortunate event that has shocked not just Mumbai city and the country but the entire world. At a time like this, it is important that we stand united against the mindless terror that is increasingly threatening to derail the economic gains that we have made as a country," said Glen Saldanha, chief executive officer and managing director of Glenmark.

Industry experts also said India's loss could be China's gain, especially in securing outsourcing. The developments could help China gains an edge as it has been terrorism free and has appeared more stable in the current meltdown, noted Ajit Kamath, chairman and managing director, Arch Pharmalabs. "India will have to assure the international community of tough measures, both on the security and economic front," he noted.

Arrow Other Stories     
- Sensex makes remarkable recovery, regains 17K
- L N Mittal doubles his stake in Ophir Energy
- Indian handicraft firms to participate in Munich fair
- Microsoft eyes Indian smartphone mkt
- RIL Hazira unit bags 'Excellent Energy Efficient Unit Award'
More  
  Read Business news in 
  Get financial advisory and solutions for your projects
  Holidays starting at a delightful EMI of Rs 3481
  Switch on and say hello to Monday morning !
  Your dream home can now be a reality.
  Visit Fortis for a preventive health check-up & get a 20% discount.
  Follow the ups and downs of your investments. Try our new Portfolio Tracker
  Kolkata Dock \ Freight contract for the British Gurkhas Nepal
  Find how Midsize Businesses use ERP to gain competitive advantage
  Trading in Forex is now as easy as 1-2-3
  Discover an economical and cost effective way to market your products and services
  Giftwithlove.com: Same day delivery of Flowers and Cakes to India
  Download the E-book on the Future of Business Intelligence
  Learn Best Practices for improving customer satisfaction
  Know your customers better... download the free e-book on CRM
   Discussion Board / User Comments    
Display Name  Email-Id  
Post your comment
Most Popular
Read
E-Mailed
Commented
   
- Kurbaan could be Karan Johar's first flop
- We are not trying for a monopoly: HAL chairman
- Ambani Jr, Brad Pitt join hands for sci-fi film
- HAL to invest Rs 25,000 cr in next 10 years
- Gap-down opening for Nifty seen
 
 More  
BS Poll
Cast Your Vote
 
   
 
Should India's defence sector be thrown open to foreign investments?
  Yes  No
Submit

  Hot Searches  
 
Amitabh Bachchan | N Chandrasekaran | Swine Flu | Mukesh Ambani | Anil Ambani | TCS | Infosys |  Air India |  Duronto |  Pranab Mukherjee | Sonia Gandhi | Congress | Rahul Gandhi |  Bigg Boss |  New Pension Scheme |  Service tax |  Excise duty |  Sebi | Tech Mahindra |  Ramalinga Raju |  Satyam |  Reliance  |  RBI |  GDP |  Gold |  Ratan Tata |  ICICI |  |  B-School | DLF  Sensex |  Tax calculator | Home Loan  | Bollywood | Personal Finance |  inflation | oil prices |  World Bank | Reliance Infratel |  HDFC |  Barack Obama  
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring
FOR HOT PRODUCTS
BS Bazaar.com
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Site Map | Contact Us | Feedback